Financial Lp Hrt Purchases 8,266 Shares of Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt bought 8,266 shares of the stock in a transaction on Thursday, July 9th. The stock was purchased at an average price of $3.38 per share, for a total transaction of $27,939.08. Following the purchase, the insider directly owned 60,540 shares of the company’s stock, valued at approximately $204,625.20. This represents a 15.81% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Friday, July 10th, Financial Lp Hrt bought 731 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average cost of $3.11 per share, for a total transaction of $2,273.41.
• On Wednesday, July 8th, Financial Lp Hrt sold 18,531 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.52, for a total value of $65,229.12.
• On Tuesday, July 7th, Financial Lp Hrt sold 10,580 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.33, for a total value of $35,231.40.
• On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.51, for a total value of $31,667.22.
• On Thursday, July 2nd, Financial Lp Hrt purchased 7,851 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average cost of $3.54 per share, with a total value of $27,792.54.
• On Wednesday, July 1st, Financial Lp Hrt acquired 3,959 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average price of $3.30 per share, for a total transaction of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt acquired 6,755 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average cost of $3.23 per share, for a total transaction of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average price of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Stock Up 40.5%

SHPH stock opened at $4.16 on Wednesday. The firm has a 50 day moving average of $4.79 and a two-hundred day moving average of $9.87. Shuttle Pharmaceuticals Holdings, Inc. has a 12 month low of $2.71 and a 12 month high of $55.90. The company has a market capitalization of $2.66 million, a price-to-earnings ratio of -0.09 and a beta of 0.29.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Connective Capital Management LLC bought a new position in shares of Shuttle Pharmaceuticals in the third quarter worth about $357,000. Geode Capital Management LLC acquired a new position in shares of Shuttle Pharmaceuticals during the 4th quarter worth about $26,000. Boothbay Fund Management LLC bought a new stake in Shuttle Pharmaceuticals during the 4th quarter valued at approximately $37,000. Finally, Ikarian Capital LLC bought a new stake in Shuttle Pharmaceuticals during the 4th quarter valued at approximately $124,000. 4.58% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on SHPH shares. Weiss Ratings upgraded shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wall Street Zen upgraded Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .